Pfizer delays drug price hikes after talking with Trump


WASHINGTON/NEW YORK (Reuters) – Pfizer Inc (PFE.N) said on Tuesday it was deferring drug price increases for no more than six months after the company’s chief executive officer had an extensive conversation with U.S. President Donald Trump.

FILE PHOTO: The Pfizer logo is seen at their world headquarters in Manhattan, New York, U.S., August 1, 2016. REUTERS/Andrew Kelly

The rollback came a day after Trump took aim at Pfizer and other U.S. drugmakers for raising prices on some of their medicines, saying in a tweet that they “should be ashamed” and that his administration would…



Read More Here

Be the first to comment on "Pfizer delays drug price hikes after talking with Trump"

Leave a comment

Your email address will not be published.


*